AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04030819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: schema therapy
Description: The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
Study NCT04543656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-Based Lifestyle Recommendations
Description: The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
Study NCT04543656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Lifestyle Recommendations
Description: The control group receives an identical activity tracker and BP monitor in order to objectively assess the effectiveness of the experimental group intervention.
Study NCT04072796 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
Study NCT02901106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl fumarate
Description: Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate
Study NCT02060903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w
Description: Abametapir Lotion 0.74% was dispensed to subjects on Day 0 for self-administration at home on the same day.
Study NCT02060903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Vehicle Lotion was dispensed to subjects on Day 0 for self-administration at home on the same day.
Study NCT02859480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5mg
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Study NCT02859480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Study NCT04400669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Bowel Preparation
Description: oral sodium phosphate (NaP) enema
Study NCT04400669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low fibre diet
Description: 3 days
Study NCT04400669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MBP plus low-fibre diet
Description: 3 days low fibre diet preoperative mechanical bowel preparation
Study NCT03709940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
Study NCT02029716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 408 Lotion 0.5%, 1%, 3%
Study NCT02029716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lotion vehicle/placebo
Study NCT02324140 — intervention group
Intervention type: OTHER
Intervention: Whole blood analysis
Description: In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
Study NCT03456791 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Human epididymis protein 4
Description: Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
Study NCT03201042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR based assay
Description: Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen).
Study NCT03201042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology based assay
Description: 1. The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~2. The Immunetics C6 Lyme ELISA assay.~3. A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~4. A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared.
Study NCT03201042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tcell based assay
Description: A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
Study NCT04195451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live-Video-Supervised Exercise Intervention
Description: The live-video-supervised exercise intervention includes exercise sessions x3/week for 3 months, and then maintenance regimen for 6 months. Maintenance includes live-video-supervised exercise sessions, only x1/week, and self-exercise x2/week following an individualized prescribed exercise program and use their heart rate monitor as an activity tracker.
Study NCT04195451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care then Live-Video Supervised Exercise Intervention
Description: Patients randomized to usual care at baseline will receive usual care for 9 months and will then start the live-video-supervised exercise intervention that includes exercise sessions x3/week for 3 months.
Study NCT03957707 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: stereotactic surgery plus thrombolysis
Description: stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
Study NCT03957707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic surgery plus thrombolysis
Description: stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
Study NCT01374620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel dose escalation
Description: Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90
Study NCT01374620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
Study NCT01374620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days
Study NCT01374620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv every 2 weeks
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 125mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 125mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 20mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: 20mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT00642577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 500mg/m2 iv weekly for 4 weeks of each 6 week cycle
Study NCT02899910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Education on lifestyle changes for treatment of metabolic syndrome
Study NCT02899910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Education on lifestyle changes for treatment of metabolic syndrome
Study NCT02899910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Training in the practice of yoga for treatment of metabolic syndrome
Study NCT02715414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Family Group + Clinic Implementation Team
Description: Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
Study NCT02715414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFG
Description: MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
Study NCT03117712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Delirium Scores
Description: * Confusion Assessment method for the ICU (CAM-ICU) and~* The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~1. Postoperative day (POD) 1~2. POD 2~3. POD 5
Study NCT03117712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carotis duplex sonography
Description: Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~1. Before induction of anaesthesia~2. Before going on cardiopulmonary bypass (CBP)~3. During CPB, 5 min after aortic cross clamping~4. After CPB~5. 24 hours after CPB
Study NCT03117712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TCD for detection of HITS
Description: Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~1. During cannulation of the ascending aorta~2. After aortic cross-clamp~3. After opening of the aortic cross-clamp~4. During decannulation
Study NCT03239704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Follow-Up
Description: Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
Study NCT03239704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Monitoring
Description: Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
Study NCT03239704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30 Day Comprehensive Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
Study NCT03239704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30 Day Comprehensive Questionnaire
Description: Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
Study NCT04495140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]PF-06882961, 50 mg
Description: A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
Study NCT04495140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
Description: A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
Study NCT03306498 — intervention group
Intervention type: DRUG
Intervention: Aminoleban (8% amino acids infusion)
Description: Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
Study NCT00075140 — intervention group
Intervention type: GENETIC
Intervention: Mutation in the gene
Study NCT01214356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
Study NCT01214356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
Study NCT00498602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 + QS-21
Description: IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
Study NCT00498602 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QS-21
Description: IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
Study NCT00498602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diluent: Phosphate Buffered Saline
Description: IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
Study NCT00498602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
Study NCT02248389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonatherm 600i ablation system
Description: HIFU ablation of tumor.
Study NCT02175498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoeopathic medicines
Description: 4 pills once a week of the indicated Similimum
Study NCT03109587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx
Description: 900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
Study NCT03109587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
Study NCT02697968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study NCT03233152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (YervoyTM, 50 mg/10 mL solution)
Description: Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec.
Study NCT03233152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (OpdivoTM, 40 mg/4mL solution)
Description: First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
Study NCT02343666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs
Description: Given IV
Study NCT02343666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT02343666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT02343666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02343666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-Benzylguanine
Description: Given IV
Study NCT02343666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given SC
Study NCT01478594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Capsules for oral administration
Study NCT01478594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution for intravenous infusion
Study NCT01478594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Study NCT01478594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m\^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m\^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m\^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
Study NCT02575365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0,5 mg Fingolimod
Description: 0.5 mg p.o fingolimod daily
Study NCT02224469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG (electrocorticography) sensing
Description: Implant electrodes and sensing device and use for control of Assistive Technology
Study NCT02301806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dieting
Study NCT02301806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dieting
Study NCT02301806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 50 mg tablet by mouth 12 weeks
Study NCT02301806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: glimepiride 1 mg tablet by mouth 12 weeks
Study NCT01928875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AoA Monitoring
Description: Monitoring with Entropy and SPI parameters during surgery